Yeddy-Shobha entered into wedlock twice; I have proof: KJP founder

Bengaluru, May 27: Aimed at giving a boost to affordable housing, the Karnataka government on Tuesday decided to slash the stamp duty on new apartments costing up to ₹35 lakh.

The decision was taken during a meeting chaired by Chief Minister B S Yediyurappa to review the progress of the Stamps & Registration department.

The Chief Minister directed that the stamp duty be cut from the existing five per cent to two per cent on apartments costing less than ₹20 lakh, getting registered for the first time, his office said in a statement.

Further, the stamp duty on apartments costing between ₹21 lakh - ₹35 lakh will be down from five per cent to three per cent, it said. It is estimated that in 2020-21 due to COVID-19 induced lockdown, Stamps and Registration department might fall short of its revenue target by ₹3,524 crore. The revenue target for 2020-21 is ₹12,655 crore.

Bengaluru, Jan 2: Prime Minister Narendra Modi on Thursday arrived at the Yelahanka air base by a special plane on a two-day visit to Karnataka to attend events in Tumakuru and Bengaluru.

Chief Minister B S Yediyurappa, Union Ministers D V Sadananda Gowda and Pralhad Joshi and state Revenue Minister R Ashoka were present to welcome Modi.

Yediyurappa greeted the Prime Minister by garlanding him and offering a shawl and adorned him with a Mysuru Peta (turban).

Later, Modi flew to Tumakuru to attend events at the Siddaganga Math apart from addressing a gathering and to present the Krishi Karman Award.

In the evening, the Prime Minister will visit the DRDO facility to dedicate five DRDO Young Scientists Laboratories to the nation.

He will stay at the Raj Bhavan on Thursday.

On Friday, Modi will inaugurate the 107th Indian Science Congress at the University of Agriculture Science in Bengaluru.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.